News & insights

First new CANTAB® product features developed & launched from the landmark INTUITION project Cambridge Cognition (AIM: COG), the neuroscience technology company, announces two new product features for its CANTAB digital cognitive assessments derived from analysis of data from the INTUITION project. ​​​Application of Expanded Normative Dataset – Increased Sensitivity and...

Collaboration integrates cognitive assessment, proprietary blood test, national phlebotomy and MRI infrastructure to accelerate patient diagnosis and care pathways throughout the UK.

The Convergence: Integrating Blood Biomarker Tests and Digital Cognition to Accelerate Alzheimer’s Research The paradigm for diagnosing and monitoring Alzheimer’s disease (AD) is shifting from relying on clinical symptoms to incorporating definitive biological evidence of amyloid and tau proteinopathy. As discussed in our recent joint webinar with C2N Diagnostics and...

Bringing Trial Activities to the Participant Lessons from the RADIAL Proof-of-Concept Trial The move toward more participant-centric clinical research has taken an important step forward. At the Clinical Pharmacology & Therapeutics journal, the first papers from the RADIAL trial, the flagship study of the Trials@Home project have now been published, offering valuable...

Speech Biomarkers for Alzheimer’s Disease Show Promise Across Multiple Languages The search for reliable, accessible biomarkers for early detection of cognitive decline has taken an important step forward. At AAIC 2025, our team presented data demonstrating that speech and language patterns can serve as valid digital biomarkers for Mild Cognitive...